Processa Pharmaceuticals' Upcoming Engagements
HANOVER, Md. -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) is thrilled to share its participation in several important investor and industry conferences this September. These events will provide an excellent opportunity for the management team to connect with investors and industry colleagues, offering insights into the company’s groundbreaking approaches to oncology treatment.
Key Conferences in September
During September, Processa Pharmaceuticals will be involved in two significant events:
H.C. Wainwright Annual Global Investment Conference
The first event is the H.C. Wainwright 26th Annual Global Investment Conference, which will be held from September 9-11, 2024, at the Lotte New York Palace Hotel. At this conference, the management team will engage in one-on-one meetings with investors and present the company’s vision. For those who cannot attend in person, the presentation will be available for on-demand viewing starting September 9, at 7:00 am Eastern time in the Investors section of Processa’s website.
European Society for Medical Oncology (ESMO) Congress 2024
Following the H.C. Wainwright conference, Processa will take part in the European Society for Medical Oncology (ESMO) Congress 2024, set to occur from September 13-17, 2024, in Barcelona. This event will be a crucial opportunity for the management team to engage with clinicians, researchers, and potential partners in the industry, with a focus on building collaborations that aim to enhance cancer treatment.
Innovations in Chemotherapy at Processa
Processa Pharmaceuticals is leading the way in the development of Next Generation Chemotherapy (NGC) drugs. These cutting-edge therapies aim to improve safety and efficacy by modifying existing FDA-approved oncology drugs. The alterations affect how these treatments are metabolized and distributed, while still preserving their core mechanisms to target and eradicate cancer cells. This strategic focus seeks to create more effective therapies that also enhance patient tolerability.
The Path Forward with Regulatory Science
A key element of Processa’s strategy is its dedication to a comprehensive Regulatory Science Approach. By effectively integrating regulatory insights with their innovative oncology pipeline, the company aims to streamline the development of new cancer therapies. The ultimate goal is to offer patients effective treatment options that not only target cancer cells but also improve their quality of life through better tolerability.
Company Contact Information
Company Contact:
Patrick Lin
(925) 683-3218
plin@processapharma.com
Investor Relations Contact:
Yvonne Briggs
LHA Investor Relations
(310) 691-7100
ybriggs@lhai.com
Frequently Asked Questions
What does Processa Pharmaceuticals focus on?
Processa Pharmaceuticals is dedicated to developing innovative chemotherapy drugs that enhance safety and efficacy for cancer treatment.
When are the conferences taking place?
The conferences will occur on September 9-11 and September 13-17, 2024.
Where is the H.C. Wainwright conference held?
The H.C. Wainwright conference will take place at the Lotte New York Palace Hotel.
What type of meetings will Processa hold at these conferences?
Management will conduct one-on-one meetings with investors and engage in discussions with industry experts and potential partners.
How can I learn more about Processa’s latest developments?
You can visit Processa Pharmaceuticals’ official website to find the latest updates and information regarding their innovative therapies.
